Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
salvia sclarea/tyrosine
Linket gemmes på udklipsholderen
13 resultater
A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Anlotinib Hydrochloride is a kind of innovative medicines approved by State Food and Drug Administration（CFDA:2011L00661） which was developed by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Anlotinib Hydrochloride is a kind of innovative medicines approved by State Food and Drug Administration（CFDA:2011L00661） which was developed by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for
Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
A Phase II Study of Anlotinib in STS Patients
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
A Phase II Study of Anlotinib in MTC Patients
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The primary objective of this trial is to explore the maximum tolerated dose(MTD), dose-limiting toxicity(DLT) of ALTN and rational dosage regimen for phase II study, to investigate the pharmacokinetics with single and multiple doses of ALTN from 5mg/d,10mg/d,16mg/d,12mg.
Den mest komplette database med medicinske urter understøttet af videnskab
- Arbejder på 55 sprog
- Urtekurer, der understøttes af videnskab
- Urtegenkendelse ved billede
- Interaktivt GPS-kort - tag urter på stedet (kommer snart)
- Læs videnskabelige publikationer relateret til din søgning
- Søg medicinske urter efter deres virkninger
- Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter
Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning
